Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer
复制标题
经治疗的转移性胃癌患者的简化 FOLFIRI
DOI：
10.1007/s00280-008-0871-y
复制
发表时间：
2009
影响因子：
3
通讯作者：
F. D. De Braud
中科院分区：
文献类型：
--
作者：
K. Lorizzo;N. Fazio;D. Radice;S. Boselli;L. Ariu;M. Zampino;F. Nolè;E. Magni;R. Ardito;I. Minchella;A. Rocca;G. Di Meglio;M. Squadroni;F. D. De Braud
目的对于接受过顺铂治疗的转移性胃癌 (MGC) 患者来说，二线化疗并不是标准选择。我们研究了伊立替康、氟尿嘧啶和叶酸的组合。方法纳入进展至顺铂化疗的患者。第 1 天给予伊立替康 180 mg/m2、亚叶酸 200 mg/m2 和氟尿嘧啶 400 mg/m2，随后立即给予氟尿嘧啶 2,400 mg/m2 46 小时连续输注（简化 FOLFIRI），每两周一次。 结果 2002 年 6 月至 2003 年 5 月期间，28 名患者接受了治疗。中位年龄为 57 岁（范围 38-68 岁）。大多数患者有远端原发灶（90%）和转移灶（71%）。 6 名患者获得部分缓解（21%，95% CI 8-41），8 名患者获得稳定疾病（21%，95% CI 13-41）。在六名有反应的患者中，三名对多西紫杉醇耐药。中位随访时间为 2.9 年，中位进展时间为 4 个月（95% CI：2-5），中位总生存期为 5 个月（95% CI 4-9）。毒性轻微，没有与治疗相关的死亡或影响生命的不良事件。结论：简化的 FOLFIRI 在接受基于顺铂化疗的未经选择的 MGC 患者中具有中等活性且耐受性良好。它在紫杉烷类药物难治性患者中的作用是有前景的，值得进一步研究。
PurposeSecond-line chemotherapy in patients with metastatic gastric cancer (MGC) pre-treated with cisplatin is not a standard option. We studied a combination of irinotecan, fluorouracil and folates.MethodsPatients progressive to cisplatin-based chemotherapy were enrolled. Irinotecan 180 mg/m2, folinic acid 200 mg/m2, and fluorouracil 400 mg/m2 were given on day 1, immediately followed by fluorouracil 2,400 mg/m2 46 h continuous infusion (simplified FOLFIRI), every 2 weeks.ResultsBetween June 2002 and May 2003, 28 patients were treated. Median age was 57 years (range 38–68). Most patients had a distal primary (90%), and metastatic disease (71%). Partial response was obtained in six patients (21%, 95% CI 8–41) and stable disease in eight (21%, 95% CI 13–41). Among the six responsive patients three were refractory to docetaxel. At a median follow-up of 2.9 years median time to progression was 4 months (95% CI: 2–5), and median overall survival was 5 months (95% CI 4–9). Toxicity was mild, without treatment-related deaths or life-treating adverse events.ConclusionsSimplified FOLFIRI was moderately active and well tolerated in unselected patients with MGC pre-treated with cisplatin-based chemotherapy. Its role in patients refractory to taxanes is promising and warrants further investigation.
影响因子：
51.1
作者：
Koizumi, Wasaburo;Narahara, Hiroyuki;Takeuchi, Masahiro
通讯作者：
Takeuchi, Masahiro
影响因子：
8.8
作者：
Kollmannsberger C;Quietzsch D;Haag C;Lingenfelser T;Schroeder M;Hartmann JT;Baronius W;Hempel V;Clemens M;Kanz L;Bokemeyer C
通讯作者：
Bokemeyer C